Department of Clinical and Experimental Medicine, University of Messina, Policlinico Universitario, Via Consolare Valeria, 98125 Messina, Italy.
University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington, KY, USA.
Curr Pharm Des. 2017;23(37):5625-5638. doi: 10.2174/1381612823666170809102258.
Prior articles paid little attention to pharmacodynamic drug interactions (DIs) between antiepileptic drugs (AEDs) and the most important psychotropic medications (antidepressants, antipsychotics, benzodiazepines and lithium) which have potential to be clinically relevant.
This article aims to provide an updated review of the potentially clinically relevant pharmacodynamic DIs between AEDs and psychotropic medications. Pharmacodynamic DIs take place directly at the site of action of a drug or indirectly by interfering with another physiological mechanism. From the clinical perspective, these DIs are classified as having 1) beneficial effects (increased efficacy and/or safety) or 2) harmful effects (decreased efficacy and/or safety).
Articles, including animal studies, were obtained from a PubMed search with no time limit. This search went beyond the articles previously found and listed in the authors' published literature reviews and DI studies.
Using knowledge of pharmacodynamic mechanisms, the potentially beneficial and dangerous pharmacodynamic DIs between AEDs and psychotropic drugs with psychotropic medications are summarized for clinicians in practical tables. The possible pharmacodynamic DIs of AEDs include 20 with antidepressants, 17 with antipsychotics, 4 with benzodiazepines and 5 with lithium.
The pharmacodynamic DIs between AEDs and psychotropic drugs have not been systematically investigated or even described in the literature. Clinicians need to become more aware of the potential for dangerous combinations of the increasingly frequent co-prescription of AEDs and psychotropic agents. Likewise, researchers need to consider these DIs in their studies, and clinicians facing cases with adverse drug reactions secondary to these pharmacodynamic DIs need to publish them.
先前的文章几乎没有关注抗癫痫药物(AED)与最重要的精神药物(抗抑郁药、抗精神病药、苯二氮䓬类药物和锂)之间的药效学药物相互作用(DI),而这些相互作用可能具有临床相关性。
本文旨在提供对抗癫痫药物和精神药物之间潜在临床相关药效学 DI 的最新综述。药效学 DI 直接发生在药物作用部位,或间接通过干扰另一种生理机制发生。从临床角度来看,这些 DI 分为 1)有益效果(增加疗效和/或安全性)或 2)有害效果(降低疗效和/或安全性)。
文章包括动物研究,通过无时间限制的 PubMed 搜索获得。该搜索涵盖了作者已发表的文献综述和 DI 研究中已发现和列出的文章之外的内容。
利用药效学机制知识,为临床医生总结了实用表格中 AED 与精神药物之间可能具有有益和危险的药效学 DI。AED 与抗抑郁药、抗精神病药、苯二氮䓬类药物和锂的可能药效学 DI 分别为 20、17、4 和 5。
AED 与精神药物之间的药效学 DI 尚未得到系统研究,甚至在文献中也没有描述。临床医生需要更加意识到 AED 和精神药物联合用药日益频繁时潜在的危险组合。同样,研究人员在研究中需要考虑这些 DI,而面临这些药效学 DI 引起的药物不良反应的临床医生需要发表这些病例。